Paraoxonase and coronary heart disease

Current Opinion in Lipidology

Volumn 9, Issue 4, 1998, Pages 319-324

  Mackness, Michael I ^a   Mackness, Bharti ^a   Durrington, Paul N ^a   Fogelman, Alan M ^b   Berliner, Judith ^b   Lusis, Aidons J ^b   Navab, Mohamad ^b   Shih, Diana ^b   Fonarow, Gregg C ^b  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLESTERASE; CHOLESTEROL ESTER; HIGH DENSITY LIPOPROTEIN; HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; NERVE GAS; ORGANOPHOSPHATE INSECTICIDE; PHOSPHOLIPID;

ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; ATHEROSCLEROSIS; DIABETES MELLITUS; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HYDROLYSIS; ISCHEMIC HEART DISEASE; LIPID OXIDATION; LIPOPROTEIN METABOLISM; NONHUMAN; OXIDATION; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; CORONARY DISEASE; ESTERASES; GENE FREQUENCY; HUMANS; LIPOPROTEINS, HDL; PHOSPHOLIPIDS; POLYMORPHISM, GENETIC; RISK FACTORS; SUBSTRATE SPECIFICITY;

MAMMALIA; MUS MUSCULUS;

EID: 0031696245     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199808000-00006     Document Type: Article

References (39)

1. Mackness MI. Possible Medical Significance of Human Serum Paraoxonase. In: Enzymes hydrolysing organophosporus compounds. Reiner E, Aldridge WN, Hoskin FCG (editors). Chichester; Ellis-Horwood: 1989. pp 202-213.
2. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991; 286:152-154.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989; 320:915-924.
4. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995; 115:243-253.
5. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
6. Watson AD, Berliner JA, Hama SY, La Du BN, Fault KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase - Inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 96:2882-2891.
7. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, et al. Effect of platelet-activating factor-acetylhydrolase on the formation and action of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 95:774-782.
8. Klimov AN, Nikiforova AA, Pleskov VM, Kuz'min AA, Kalashnikova NN, Antipova TO. The protective action of high-density lipoproteins, their subfractions and lecithin-cholesterol acyltransferase in the peroxide modification of low-density lipoproteins. Biokkimiya 1989; 54:118-123.
9. 2 as substrates for PON1 indicating PON1 has peroxidase like activity.
10. Shih DM, Gu L, Hama S, Xia Y-R, Navab M. Fogelman AM, Lusis AJ. Genetic-dietary regulation of serum paraxonase expression and its role in atherogenesis in a mouse model. J Clin Invest 1996; 97:1630-1639.
11. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Carlinez CJ, Castellani LW, et al. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 1997; 99:2005-2019.
12. Shih DM, Gu L, Xia Y-R, Navab M, Li W-F, Hama S, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998 In press. The first description of transgenically modified mice which lack PON1. These mice are at increased susceptibility to organophosphate poisoning and atherosclerosis indicating a central role for PON1 in vivo in protecting against both. This is particularly important for the antiatherogenic properties of PON1 which had previously only been shown in in-vitro systems.
13. Mackness B, Durrington PN, Mackness MI. Lack of protection against oxidative modification of LDL by avian HDL. Biochem Biophys Res Comm 1998 (in press) This manuscript provides further evidence that HDL lacking PON1 is unable to protect LDL from oxidation and provides an alternative model to expensive transgenic animals.
14. Watson. AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272:13597-13607. The first structural identification of the proinflammatory oxidation products of arachidonic acid found in minimally modified LDL which are believed to act as substrates for PON1 and are present in vivo.
15. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993; 52:598-608.
16. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genetics 1993; 3:73-76
17. Davies HG, Richter RJ, Keifer M, Broomfield CA, Sowalla J, Furlong CE. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genetics 1996; 14:334-336.
18. Blatter-Garin M-C, James RW, Dussoix P, Blanché H. Passa P, Froguel P, Ruiz J. Paraoxonase Polymorphism Met-Leu 54 is associated with modilied serum concentrations of the enzyme. J Clin Invest 1997; 99:62-66.
19. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol 1997; 112:265-268.
20. Primo-Parma, SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomic 1996; 33:498-509.
21. Hegele RA, Connelly PW, Scherer SW, Hanley AJG, Harris SB, Tsui L-C, Zinman B. Paraoxonase-2 Gene (PON2) G148 variant associated with elevated fasting plasma glucose in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82:3373-3377.
22. Ruiz J, Blanché H, James RW, Blatter-Garin M-C, Vaise C, Charpeutier G. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 1995; 346:869-872.
23. Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest 1995; 96:3005-3008.
24. Herrmann SM. Blanc H, Poirier O, Arveiter D, Luc G, Evans A, et al. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM study. Atherosclerosis 1996; 126:299-304.
25. Antikainen M, Murtomäki S, Syvänne M, Pahlman R, Tahvanainen E, Jauhiainen, et al. The Gln-Arg 191 Polymorphism of human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. J Clin Invest 1996; 98:883-885.
26. Suehiro T, Nakauchi Y, Yamamoto M, Arii K, Itoh H, Hamashige N, Hashimoto K. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease. Int J Cardiol 1996; 57:69-73.
27. Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Throm Vasc Biol 1997; 17:1067-1073.
28. 192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997; 82:2257-2260.
29. Zama T, Murata M, Matsubara Y, Kawano K, Aoki N, Yoshino H, et al. A 192-Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17:3565-3569.
30. Lansbury AJ, Calto AJ, Carter AM, Bamford JM, Grant PJ. The paraoxonase glutamine/arginine polymorphism and cerebrovascular disease. Cardiovasc Dis 1997; 7:353-356.
31. Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 1998; 62:36-44. An indication of the potentially complicated genetic interrelationships predisposing PON1 to CHD.
32. Sanghera DK, Saha N, Kamboh MI. The codon 55 polymorphism of the paraoxonase 1 gene is not associated with risk of coronary heart disease in Asian Indians and Chinese. Atherosclerosis 1998; 136:217-223.
33. Mackness MI, Arrol S, Mackness B, Durrington PN. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet 1997; 349:851-852.
34. Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letts 1998; 423:57-60. This manuscript describes how the presence of the different PON1 isoenzymes governs the ability of HDL to protect LDL against oxidative modification. This is apparently due to the differential rates of hydrolysis ot lipid peroxides by the PON1 isoenzymes.
35. Mackness MI, Patel B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7:69-76.
36. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoprotein. Arterioscler Thromb Vasc Biol 1995; 11:1812-1818.
37. Mackness MI, Durrington PN. Paraoxonase: another factor in NIDDM cardiovascular disease (letter). Lancet 1995; 346:856.
38. Mackness B, Hunt R, Durrington PN, Mackness MI. Increased immunolocalistion of paraoxonase, clusterin and apolipoprotein Al in the human artery wall with progress of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:1233-1238. This manuscript provided the first evidence that PON1 was present in the artery wall and that it and the other components of the PON1 specific HDL subspecies accumulated in the artery wall as atherosclerosis progressed.
39. Mackness MI, Mackness B, Arrol S, Wood G, Bhatnagar D, Durrington PN. Presence of paraoxonase in human interstitial fluid. FEBS Lett 1997; 416:377-380.